Table 3. Cox model of time to salvage ADT use after primary prostatectomy or radiotherapy among men with newly diagnosed localized prostate cancer, including only baseline predictors.
| Prostatectomy (N = 16,445) HR (95 % CI) | Radiotherapy (N = 19,531) HR (95 % CI) | |
|---|---|---|
| Age at diagnosis (years) | ||
| 35–59 (ref) | 1.00 | 1.00 |
| 60–64 | 1.14 (1.02, 1.27)* | 1.06 (0.91, 1.24) |
| 65–69 | 1.03 (0.91, 1.16) | 1.17 (1.01, 1.34)* |
| 70+ | 1.76 (1.53, 2.03)** | 1.23 (1.08, 1.40)** |
| Race | ||
| White (ref) | 1.00 | 1.00 |
| Black | 1.24 (1.11, 1.38)** | 1.09 (0.97, 1.22) |
| Hispanic | 1.06 (0.94, 1.21) | 1.10 (0.96, 1.25) |
| All others | 0.92 (0.77, 1.11) | 0.97 (0.83, 1.13) |
| Gleason score (baseline) | ||
| ≤6 (ref) | 1.00 | 1.00 |
| 7 | 1.50 (1.37, 1.66)** | 1.67 (1.53, 1.83)** |
| 8 | 2.44 (2.07, 2.87)** | 2.35 (2.05, 2.68)** |
| 9–10 | 3.74 (3.09, 4.53)** | 3.39 (2.90, 3.97)** |
| PSA (baseline, ng/mL) | ||
| ≤4 (ref) | 1.00 | 1.00 |
| 4 < PSA ≤ 10 | 0.92 (0.82, 1.03) | 1.03 (0.89, 1.19) |
| 10 < PSA ≤ 20 | 1.32 (1.15, 1.52)** | 1.44 (1.24, 1.69)** |
| PSA > 20 | 2.46 (2.08, 2.91)** | 2.41 (2.05, 2.83)** |
| T stage | ||
| ≤T2A (ref) | 1.00 | 1.00 |
| T2B | 1.29 (1.13, 1.47)** | 1.33 (1.19, 1.49)** |
| T2C+ | 0.90 (0.80, 1.01) | 1.16 (1.05, 1.29)** |
| Tumor sequence | ||
| Single primary (ref) | 1.00 | 1.00 |
| 1st of multiple | 1.33 (1.14, 1.54)** | 1.13 (0.99, 1.28) |
| 2nd or more | 1.03 (0.85, 1.25) | 1.03 (0.88, 1.21) |
| Elixhauser score | ||
| 0 (ref) | 1.00 | 1.00 |
| 1 | 1.09 (0.98, 1.21) | 1.07 (0.96, 1.18) |
| 2 | 1.17 (1.02, 1.32)* | 1.22 (1.09, 1.37)** |
| 3+ | 1.31 (1.13, 1.51)** | 1.31 (1.17, 1.48)** |
Models adjusted for diagnosis year and health plan
HR hazard ratio, CI confidence interval, ADT androgen deprivation therapy, PSA prostate-specific antigen
*
p < 0.05;
**
p < 0.01